Federal investigators have closed a national review of severe reactions following injections of ceftriaxone, one of the most widely used antibiotics in American clinics and hospitals, and their central finding is that nothing was wrong with the drug itself. The review identified 31 cases involving death or cardiopulmonary resuscitation across 18 states, including 12 deaths. Product testing turned up no tampering, no adulteration, no endotoxin, and no purity or potency problems.
That combination matters for anyone who has been handed a prescription for an injectable antibiotic. The findings, published in Clinical Infectious Diseases and summarized by CIDRAP, point to rare but severe reactions to a familiar medicine rather than a bad batch moving through the supply chain. There is no recall to check and no lot number to look up.
